Streetbeat News

Products Services

F

Ford Motor Co (NYSE:F) announced a recall of 42,652 Bronco Sport and Escape vehicles in the U.S. due to broken fuel injectors that could cause fires. This coincided with the death of O.J. Simpson, who is historically linked to the Ford Bronco from a famous 1994 police chase. Ford has distanced itself from the negative connotations associated with Simpson and the Bronco, focusing on its revival and distancing from its past image.

Portfolio Pulse from Chris Katje

April 12, 2024 | 7:02 pm

SHIB-USD

'Dogecoin Killer' Shiba Inu (SHIB) has seen a significant increase in daily transactions, with a 3,555% surge, and its burn rate spiked by 1,465%. This indicates a bullish sentiment among investors. Shiba Inu's lead developer, Shytoshi Kusama, expressed enthusiasm for contributing to the Content Delivery Security Association with blockchain technology. Additionally, D3 Global now accepts Shiba Inu and BONE for payments on Shibarium.

Portfolio Pulse from Khyathi Dalal

April 12, 2024 | 6:56 pm

TRMB

Trimble (NASDAQ:TRMB) is set to change its financial reporting segments to 'Architects, Engineers, Construction and Owners' (AECO), 'Field Systems', and 'Transportation and Logistics' (T&L), starting from Q1 2024. This reorganization aims to align financial reporting with the company's structure and business models, covering software solutions for construction, hardware-centric businesses, and services for long haul trucking and freight shippers.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 6:31 pm

ABBV

AbbVie Inc (NYSE:ABBV) released interim results from a Phase 3 study on atogepant for migraine prevention, showing improved outcomes and consistent safety profiles. Despite positive data, ABBV shares dropped 2.75% to $162.92, with trading volume lower than average. The company also raised its revenue outlook for Ubrelvy and Qulipta, expecting over $3 billion in peak revenues, up from previous estimates.

Portfolio Pulse from Vandana Singh

April 12, 2024 | 6:19 pm

AGEN

BMY

Agenus Inc (NASDAQ:AGEN) reported promising Phase 1 trial results for its BOT/BAL therapy in metastatic colorectal cancer, with a 23% overall response rate. The company plans to submit a BLA later this year and present detailed Phase 2 results in 2024. Agenus also executed a one-for-twenty reverse stock split. Despite positive data, funding concerns persist as Agenus ended 2023 with $76.1 million in cash and a significant cash burn. William Blair remains optimistic, maintaining an Outperform rating with a sales forecast of $404 million by 2027 for the therapy.

Portfolio Pulse from Vandana Singh

April 12, 2024 | 6:18 pm

ARB

BEAM

RNDR

Popular crypto analyst Altcoin Sherpa shared his 2024 predictions for three altcoins: BEAM, ARB, and RNDR. He is 'hugely bullish' on BEAM, sees challenges for ARB with a potential decline to $1.20, and is optimistic about RNDR's recovery, suggesting buy-in points at the .382 and .50 Fibonacci retracement levels.

Portfolio Pulse from Murtuza Merchant

April 12, 2024 | 5:55 pm

LUNR

SPCE

Blue Origin, founded by Jeff Bezos, announced its 7th crewed flight, NS-25, with a six-person crew, marking a return to human spaceflight after setbacks. The crew includes notable figures such as Ed Dwight and entrepreneurs from various fields. This follows a period of inactivity due to issues in an uncrewed flight in September 2022. The announcement comes amid increased interest in space travel, with recent achievements by Intuitive Machines and plans by Virgin Galactic to focus on profitability.

Portfolio Pulse from Chris Katje

April 12, 2024 | 5:47 pm

CRM

FEPI

MRAD

RBC Capital analyst Rishi Jaluria reiterated Salesforce Inc (CRM) with an Outperform rating and raised the price target from $325 to $350, citing enthusiasm for generative AI, significant growth in Data Cloud ARR, and impressive margin expansion. Salesforce's strategic focus on AI and Data Cloud is expected to drive long-term growth and margin gains, despite no immediate revenue from GenAI. The company's stock has seen a 55% increase over the last 12 months, and exposure to CRM can also be gained through FEPI and MRAD ETFs.

Portfolio Pulse from Anusuya Lahiri

April 12, 2024 | 5:42 pm

BLK

BlackRock, Inc. (NYSE:BLK) reported Q1 revenue growth of 11% year over year to $4.728 billion, beating consensus but saw shares trading lower due to concerns over fee rate dynamics. Management fees missed consensus by 1%, with equity fee rates and Alts fee rate declining. iShares drove $55 billion of flows, and despite mixed results, future growth is anticipated with significant mandates in wealth, institutional, and Aladdin sectors.

Portfolio Pulse from Nabaparna Bhattacharya

April 12, 2024 | 5:27 pm

CTLT

LLY

NVO

BMO Capital Markets initiated coverage on Novo Nordisk A/S (NVO) with an Outperform rating, highlighting its dominance in the obesity and diabetes drug market. The analysis points to Novo Nordisk and Eli Lilly (LLY) as leading players in this sector, with Novo's strong pipeline, including CagriSema and INV-202, expected to drive growth. The market, projected to reach over $130 billion, sees Novo and Lilly benefiting from manufacturing capabilities, with Catalent Inc (CTLT) also mentioned as a bolster to Novo's position. Trials for CagriSema and semaglutide are anticipated to push shares higher.

Portfolio Pulse from Vandana Singh

April 12, 2024 | 5:22 pm